MME and heart failure: A recent clinical trial on 592 patients from 137 centres in 20 countries were randomized 1:1 to either LCZ696 (target dose 97/103 mg twice daily) or valsartan (target dose 160 mg twice daily) showed no evidence that NEP inhibition increased the risk of cognitive impairment in patients with heart failure.59